INTRODUCTION- The advances in polymer chemistry have paved the way
for new technologies in drug delivery. These advances resulted in polymers with
distinctive properties. Initially, polymers have been used as solubilizers and
drug stabilisers and for continuing drug release mechanics. At that time, the
roles of polymers have developed. A new synthetic method was developed to produce
polymers with a well-defined structure [1-6]. With the availability
of new monomers, polymers with a range of phenotypes and personalised
properties may be synthesised. As a result of feedback from other scientific
fields such as biochemistry, microfluidics and nanotechnology, polymers and
their pathways for drug delivery have gotten smarter and more efficiently. With
the introduction of new polymers with unique properties, selecting the right
polymers for particular applications is becoming exceedingly important. As a
result, high demand has been made for safe and realistic vehicles for the
transport of drugs. When new polymers were made available with new features,
the market for polymers with more complex properties grew. Ideal, if advanced
polymers are synthesised with unique drug delivery features such as medication
solutions and drug targeting and for solving emerging problems [7-12]. As a consequence, the new drug delivery mechanisms and the
peculiar features of polymers are beneficial to grasp. The main aims of this
analysis are to provide an outline and describe future technology forecasts for
advances in polymers and polymers for drug delivery. The numbers of
publications discussing advanced drug delivery technologies have risen in
recent years to enhance the time-scale and/or distribution management of the
release. This analysis highlights some of the latest developments. Due to a
large number of papers written and the small space for this report [12-20], it is almost difficult to provide an outline of the topic.
Rather, with new literature illustrations, wir selected two distinct approaches
for designing advanced copolymer-based drug deliveries. In the remaining parts
of this article, we explore the use of practical block copolymers and the use
of auxiliary agents. Cross-connecting groups to block copolymers can enhance
the stability and temporal regulation of the associated micelles.
Modern polymers for the design of
theranostics- A disease development usually requires
several biological elements such as growth factors, enzymes, and leukocytes. To
overcome this etiological problem, the concept of the therapeutic window can be
generalised to include a therapeutic period so each variable's time frames
become a crucial parameter. For eg, the ischemic brain induces multiple
cellular activities, such as excitatory amino acid and reactive hour-long
development of oxygen species, a day's creation of polymorphonuclear leucocyte,
and macrophage activation throughout a week [21-30].
The clinical time window can be used for
tissue engineering depending on drug delivery. Normal tissues require temporary
stimulus to achieve special function in the body during their growth. Several
growth factors, such as the fibroblast growth factor, insulin-like growth
factor, platelet-based growth factor, bone morphology protein transforming,
vascular endothelial growth factor, etc., play a part in bone regeneration [31-38].
As an expansion of the pulsatile release scheme, a temporary drug release
device is the perfect way to supply certain drugs. Sequential release of
multiple drug components is only needed in this method (Fig. 1). In addition to
programming, the controlled release system is also a major advantage in the
on-site release of drugs. Techniques for targeting are commonly used to unleash
on site. To optimise therapeutic effectiveness while minimising side effects
this process strongly regularises the release of drugs. Drug release at a high
local dose is limited for a long time to one particular target site. More
controllability can generally be linked to the increased complexity of the
structure. This is a key to the advancement of effective drug delivery systems,
such as how to select an optimal drug delivery system and how to minimise the
sophistication of the system [39-46].
.png)
Fig. 1: Depicts the multifunctional application of
polymer-based deliverables
Sensitive biopolymers for bioactive
delivery- Polymers that react to biomolecules are interesting
since they can be more accurate to physical or chemical stimuli than polymers.
A well-known example of this is glucose-sensitive polymers used for the
treatment of diabetes with phenyl-boronic acid, glucose oxidase (GO) or
concanavalin A (ConA). The release of insulin could be closely regulated by a
system of closed-loop feedback in such systems. Their practical usefulness was
sadly extremely limited. It was difficult to stop proteins like GOx and ConA,
causing a polymer system's protein leakage and a host immune response. Besides,
some monosaccharides may fight for binding glucose sites. Glutathione, which
governs the cell redox state and mostly is present in the cytoplasm, is also an
important molecule. Glutathione can easily break disulfide bonds in a polymer because
of its great reduction activity. Michaels can grow when a disulfide is
attached to a PEG-end and good therapeutic efficacy can be achieved in vitro
after endocytosis (ODN) and small ribonucleic acid (SiRNA). As most conditions
equate with enzyme action, a great deal of interest has recently been gained by
enzyme-sensitive polymer and polymeric structures. Polymer-doxorubicin combined
with peptide bridges were planned for the discovery of doxorubicin from the
tumour site, PEG-doxorubicin, N-(2-hydroxy-propyl) methacrylamide (HPMA). The
Peptide Linkers had to be enzymatically degraded in the lysosome, leading to a
high doxorubicin concentration in the target cells [47–56]. Polymer
micelles have reported responding to protein kinase A (PKA). PKA will increase
the density of the negative charge and allow therapeutic genes to dissociate
themselves from the polymer spine by the phosphorylation of PKA substrate
peptides labelled by these micelles. Another important function of polymer
conjugation is the solubility of poorly soluble medicines. The change is a
little molecular compound often leads to a lack of bioactivity due to the
structural-activity relationship. The high hydrophobicity of drugs that are not
water-soluble leads often to their bioactivity. Nonetheless, several chemical
changes may be made without causing a loss in the process. The feature groups
already in the framework of medicines will combine water-soluble polymers to
contribute to a significant increase in the solubility of drugs. Acid/base or
enzyme-mediated hydrolysis may restore the original structure of medicine. The
copolymers HPMA conjugating paclitaxel and doxorubicin are strong examples and
many other polymer-drug conjugates in clinical trials are researched [57-78].
These polymer-medicinal combinations require however also a chemical
modification of existing products which entails higher costs and the need for
purification. Also, polymer conjugation generates new chemical medicines, which
require FDA authorisation even if the original medicine has been licensed [79,80].
.png)
Fig. 2: Depicts the various deliverable systems for
bioactive
CONCLUSIONS- Nanocarriers have been evolving with
advances in the science and engineering of polymers in multifunctional
application systems, such as controlled medicine distribution systems. To
overcome and improve the vulnerabilities of conventional drug systems for spatiotemporal
control of multiple drugs, sustained and pulsatile release systems, as well as
polymer-drug conjugates, were created. Parallel synthesis is a useful way to
identify new polymers suitable for various biomedical applications. Different
methods of targeting and intelligent polymer networks guarantee to program and
on line releases for therapeutic drugs. Currently, controlled medication supply
networks incorporate a variety of components in one carrier and aim to fill
different functions concurrently. Also, interdisciplinary research helps the
development of more integrated and complex polymer structures not only to
optimise therapeutic effectiveness but also for a single drugs carrier's
multifunctional. But identifying clinically applicable medicines can be
difficult given the various drug delivery systems available. The safety issue
should often be taken into consideration when planning a new product since
medication supply devices are meant to be inserted into the body. As
anticipated, several drug carriers had significant problems with approval
procedures and clinical trials. Study into a modern, more efficient method
should then pursue efforts to establish a healthy and mass manufacturing system
for medicinal drugs.
CONTRIBUTION OF AUTHORS
Supervision- Roberto
Jetsu, Pavan Kalian
Materials- Roberto
Jetsu, Pavan Kalyan, Hima Bindu
Data Collection- Pavan
Kalyan, Hima Bindu
Literature Search- Roberto
Jetsu, Pavan Kalyan,
Writing Article-
Roberto Jetsu, Pavan Kalyan, Hima Bindu
Critical Review
- Pavan Kalyan,
Article Editing-
Roberto Jetsu, Pavan Kalyan, Hima Bindu
Final
Approval- Roberto
Jetsu, Pavan Kalyan
REFERENCES
1.
Yu Z, Xu Q, Dong C, Lee
SS, Gao L, et al. Self-assembling peptide nanofibrous hydrogel as a versatile
drug delivery platform. Curr Pharm Des.,
2015; 21(29): 4342-54.
2.
Abdelhady S, Khaled MH,
Mallesh K. Electro spun-nanofibrous mats: a modern wound dressing matrix with a
potential of drug delivery and therapeutics. J Eng Fibers Fabrics,
2015; 10(4): 179-93.
3.
Li WJ, Robert LM, Rocky
ST. Electrospun nanofibrous scaffolds: production, characterization, and
applications for tissue engineering and drug delivery. J Biomed
Nanotechnol., 2005; 1(3): 259-75.
4.
Ahmed, Osama AA,
Mallesh K, Zainy MB, Mohsen IA, et al. Quality by design coupled with near
infrared in formulation of transdermal glimepiride liposomal films. J
Pharma Sci., 2015; 104(6): 2062-75.
5.
Alhakamy NA, Osama AA,
Mallesh K, et al. Chitosan-based microparticles enhance ellagic acid’s colon
targeting and proapoptotic activity. Pharm., 2020; 12(7): 652.
6.
Garg T, Goutam R, Amit
KG. Biomaterials-based nanofiber scaffold: targeted and controlled carrier for
cell and drug delivery. J Drug Targeting, 2015; 23(3): 202-21.
7.
Kurakula M, Raghavendra
N. Electrospraying: A Facile Technology Unfolding the Chitosan based Drug
Delivery and Biomedical Applications. Euro Polymer J., 2021; 110326.
8.
Yao Q, Yangxi L,
Balaranjan S, Ranjit TK, Hongli S. Mesoporous silicate nanoparticles/3D
nanofibrous scaffold-mediated dual-drug delivery for bone tissue engineering. J
Controlled Release., 279 (2018): 69-78.
9.
Hasnain MS, Vema K,
Mallesh K, Koteswara R, Mohammad T, et al. Use of alginates for drug delivery
in dentistry. In Alginates in Drug Delivery, Academic Press; 2020; pp.
387-404.
10.
He C, Wei N, Wei F.
Engineering of biomimetic nanofibrous matrices for drug delivery and tissue
engineering. J Materials Chem., 2014; 45(2): 7828-48.
11.
Hasnain MS, Nayak AK,
Kurakula M, Hoda MN. Alginate nanoparticles in drug delivery. In Alginates in
Drug Delivery, 2020; pp. 129–52.
12.
Ji W, Fang Y, Hajar S,
et al. Biocompatibility and degradation characteristics of PLGA-based
electrospun nanofibrous scaffolds with nanoapatite incorporation. Biomaterials,
2012; 33(28): 6604-14.
13.
Hosny KM, Hibah M.
Aldawsari RH, et al. Preparation, optimization, and evaluation of hyaluronic
acid-based hydrogel loaded with miconazole self-nanoemulsion for the treatment
of oral thrush. AAPS Pharm Sci Tech., 2019; 20(7): 1-12.
14.
Liu X, Xiaobing J,
Peter XM. Nanofibrous hollow microspheres self-assembled from star-shaped
polymers as injectable cell carriers for knee repair. Nature
materials, 2011; 10 (5): 398-406.
15.
Kurakula M, Tarek AA.
Co-delivery of atorvastatin nanocrystals in PLGA based in situ gel for
anti-hyperlipidemic efficacy. Current drug delivery, 2016; 13(2):
211-20.
16.
Lu Q, Xiuli W, Shenzhou
L, Mingzhong L, David LK, et al. Nanofibrous architecture of silk fibroin
scaffolds prepared with a mild self-assembly process. Biomat., 2011;
32(4): 1059-67.
17.
Kurakula M, Osama AA,
Usama AF, Tarek A. Solid lipid nanoparticles for transdermal delivery of
avanafil: optimization, formulation, in-vitro and ex-vivo studies. J
Liposome Res., 2016; 26(4): 288-96.
18.
Liang D, Benjamin SH,
Benjamin C. Functional electrospun nanofibrous scaffolds for biomedical
applications. Adv Drug Delivery Rev., 2007; 59(14): 1392-412.
19.
Kurakula M, El-Helw AM,
Tariq RS, Magdy YA. Chitosan based atorvastatin nanocrystals: effect of
cationic charge on particle size, formulation stability, and in-vivo
efficacy. Inter J Nanomed., 2015; 10: 321.
20.
Shi Y, Yue L, Jianming
W, Weiguo W, et al. A novel transdermal drug delivery system based on
self-adhesive Janus nanofibrous film with high breathability and
monodirectional water-penetration. J Biomaterials Sci., Polymer Edition,
2014; 25(7): 713-28.
21.
Kurakula M, Koteswara
R. Moving polyvinyl pyrrolidone electrospun nanofibers and bioprinted scaffolds
toward multidisciplinary biomedical applications. Eur Polymer J., 2020;
109919.
22.
Miszuk JM, Jue H,
Hongli S. Biomimetic Nanofibrous 3D Materials for Craniofacial Bone Tissue
Engineering. ACS Applied Bio Materials, 2020; 3(10): 6538-45.
23.
Kurakula MN,
Raghavendra N, Khushwant SY. Formulations for Polymer Coatings. Polymer
Coatings: Technol Appl., 2020; 415-43.
24.
Monteiro N, Diana R,
Albino M, Susana F, Nuno A, et al. Instructive nanofibrous scaffold comprising
runt-related transcription factor 2 gene delivery for bone tissue
engineering. Acs Nano., 2014; 8(8): 8082-94.
25.
Fereiduni E, Ali G,
Mohamed E. Characterization of composite powder feedstock from powder bed
fusion additive manufacturing perspective. Materials, 2019; 12(22):
3673.
26.
Kim HS, Hyuk SY.
MMPs-responsive release of DNA from electrospun nanofibrous matrix for local
gene therapy: in vitro and in vivo evaluation. J Controlled
Release, 2010; 145(3): 264-71.
27. Kurakula M, Koteswara R, Vema K, Md Saquib H, Amit KN.
Alginate-based hydrogel systems for drug releasing in wound healing.
In Alginates in Drug Delivery, Academic Press, 2020; pp. 323-358.
28. Xi Y, Juan G, Yi G, Bo L, Peter XM. Biomimetic elastomeric polypeptide-based
nanofibrous matrix for overcoming multidrug-resistant bacteria and enhancing
full-thickness wound healing/skin regeneration. ACS nano, 2018; 12,
11: 10772-84.
29.
Rao K, Mallesh K,
Khushwant SY. Application of Electrospun Materials in Gene Delivery. Electrospun
Materials Allied Appl., 2020: 265-306.
30.
Holzwarth JM, Peter XM.
Biomimetic nanofibrous scaffolds for bone tissue
engineering. Biomaterials, 2011; 32(36): 9622-29.
31.
Kurakula M, Koteswara
R. Pharmaceutical Assessment of Polyvinylpyrrolidone (PVP): As Excipient from
Conventional to Controlled Delivery Systems with a Spotlight on COVID-19
Inhibition. J Drug Delivery Sci Technol., 2020: 102046.
32.
Hakkarainen E, Arle K,
Ivo L, Andres L, Kristian S, et al. Comparison of traditional and ultrasound-enhanced
electrospinning in fabricating nanofibrous drug delivery systems. Pharma.,
2019; 11(10): 495.
33.
Kurakula M, Tariq
RSobahi, El-Helw AM, Magdy YA. Development and validation of a RP-HPLC method
for assay of atorvastatin and its application in dissolution studies on
thermosensitive hydrogel-based nanocrystals. Tropical J Pharma Res.,
2014; 13(10): 1681-87.
34.
Bagó JR, Guillaume JP,
Onyi O, Mahsa MA, Elizabeth GL, et al. Electrospun nanofibrous scaffolds
increase the efficacy of stem cell-mediated therapy of surgically resected
glioblastoma. Biomaterials, 2016; 90: 116-25.
35.
Kurakula MC, Nagasree
K, Prakash VD. Formulation and evaluation of prednisolone proliposomal gel for
effective topical pharmacotherapy. Inter J Pharma Sci Drug Res.,
2012; 4(1): 35.
36.
Bacakova L, Marketa B,
Julia P, Radmila K, Lubica S, et al. Nanofibrous scaffolds as promising cell
carriers for tissue engineering. In Nanofiber Research-Reaching New
Heights, Intech Open, 2016; pp. 29-53.
37. Mallesh K, Nikitha P, Chowdary P, Kumar R. Piroxicam proliposomal
gel: a novel approach for tropical delivery. J Pharma Res.,
2012; 5(3): 1755-63.
38. Kurakula M, Abdul BM, Rao PA, Prakash VD. Estimation of
piroxicam in proliposomal formulation using RPHPLC method. Int J Chem Anal
Sci., 2011; 2(9): 1193-96.
39.
Kurakula MN,
Raghavendra N. Prospection of recent chitosan biomedical trends: Evidence from
patent analysis (2009–2020). Int J Biol Macromolecul., 2020; 165(Pt B): 1924-38.
40.
Sun J, Huaping T.
Alginate-based biomaterials for regenerative medicine applications. Materials,
2013; 6(4): 1285-309.
41. Venkatesh M, Kurakula M. Self-nano emulsifying drug delivery
system (SNEDDS) for oral delivery of atorvastatin-formulation and
bioavailability studies. J Drug Delivery Therapeutics, 2013; 3(3): 131-40.
42. Lee S, Jung SK, Hun SC, Go WK, Jong IW, et al. Electrospun
nanofibrous scaffolds for controlled release of adeno-associated viral
vectors. Acta Biomaterialia, 2011; 7(11): 3868-76.
43.
Diwan PV, et al.
Estimation of Prednisolone in Proliposomal formulation using RP HPLC method.
2011; 2(9): 1193-96.
44.
Chan OCM, So KF, Chan
BP. Fabrication of nano-fibrous collagen microspheres for protein delivery and
effects of photochemical crosslinking on release kinetics. J Controlled
Release, 2008; 129(2): 135-43.
45.
Murali VP, Tomoko F,
Caleb G, et al. Modified electrospun chitosan membranes for controlled release
of simvastatin. Int J Pharma., 2020; 119438.
46.
Feng ZQ, Xuehui C, Ning
PH, Tao W, et al. The effect of nanofibrous galactosylated chitosan scaffolds
on the formation of rat primary hepatocyte aggregates and the maintenance of
liver function. Biomaterials, 2009; 30 (14): 2753-63.
47.
Naveen NR, Kumar SB,
Uma TS, Natrajan TS, Sehgal PK. Synthesis of nonwoven nanofibers by
electrospinning–a promising biomaterial for tissue engineering and drug
delivery. Adv Eng Materials, 2010 12 (8): B380-87.
48.
Kalmer RR, Maedeh M,
Ghasem N, Mortaza G, Yaghoub H, et al. Fabrication of multifunctional
microfibrous and nanofibrous cellulose carriers and comparison of cell adhesion
and spreading potential on them. Biointerface Res Appl Chem.,
2020; 10(3): 5387-91.
49.
Pilehvar-Soltanahmadi
Y, Mehdi D, Abbas M, et al. An overview on application of natural substances
incorporated with electrospun nanofibrous scaffolds to development of
innovative wound dressings. Mini reviews Medicinal Chem.,
2018; 18(5): 414-27.
50.
Naveen NR, Chakka G,
Mallesh K. Okra-Thioglycolic acid conjugate-Synthesis, characterization, and
evaluation as a mucoadhesive polymer. Processes, 2020; 8(3): 316.
51.
Naveen NR, Chakka G, Mallesh
K. Okra-Thioglycolic acid conjugate-Synthesis, characterization, and evaluation
as a mucoadhesive polymer. Processes, 2020; 8(3): 316.
52.
Raghavendra NN,
Kurakula M, Gowthami B. Process optimization by response surface methodology
for preparation and evaluation of methotrexate loaded chitosan nanoparticles.
Materials Today: Proceedings, 2020; 33(7): 2716-24.
53.
Jayarama R, Venugopal
SR, Rajeswari R, Shayanti M, Ramalingam B, et al. Nanofibrous structured biomimetic
strategies for skin tissue regeneration. Wound Repair Regeneration,
2013; 21(1): 1-16.
54.
Ingavle GC, Kent L.
Advancements in electrospinning of polymeric nanofibrous scaffolds for tissue
engineering. Tissue Eng Part B Rev., 2014; 20(4): 277-93.
55. Vanitasagar SC, Srinivas NJ, Subhashini P, Mallesh LA. Solid
dispersion-a comparative study on the dissolution rate of aceclofenac. Int
J Pharm Pharmaceutical Sci., 2012; 4(3): 274-78.
56. Zhong W, Malcolm MQX, Howard IM. Nanofibrous materials for
wound care. Cutaneous Ocular toxicol., 2010; 29(3): 143-52.
57. Hosny KM, Nabil AA, Maeen AA, Mallesh K, Alshaimaa MA, et al.
Self-Nanoemulsifying System Loaded with Sildenafil Citrate and Incorporated
within Oral Lyophilized Flash Tablets: Preparation, Optimization, and In Vivo Evaluation. Pharmaceutics,
2020; 1211: 1124.
58. Prabaharan M, Jayakumar R, Nair SV. Electrospun nanofibrous
scaffolds-current status and prospects in drug delivery. Biomedical
applications of polymeric nanofibers, 2011: 241-62.
59. Modica de ML, Alison VK, Maria de FP, Bahijja TR. Engineering
of nanofibrous amorphous and crystalline solid dispersions for oral drug
delivery. Pharmaceutics, 2019; 11 (1): 7.
60. Kurakula M. Probiotics in Lung Cancer: An Emerging Field of
Multifarious Potential and Opportunities. In Probiotic Research in
Therapeutics, pp. 125-158. Springer, Singapore, 2021.
61. Li WJ, Robert LM, Rocky ST. Electrospun nanofibrous
scaffolds: production, characterization, and applications for tissue
engineering and drug delivery. J Biomed Nanotechnol., 2005; 1(3): 259-75.
62. Basim P, Gorityala S, Kurakula M. Advances in Functionalized
Hybrid Biopolymer Augmented Lipid-based Systems: A Spotlight on Their Role in
Design of Gastro Retentive Delivery Systems. Biopolymers, 2021, pp.
4.
63. Basha SK, Dhandayuthabani R, Muzammil MS, Kumari VS. Solid
lipid nanoparticles for oral drug delivery. Materials Today:
Proceedings, 2021, pp. 313-24.
64. Jeengar MK, Mallesh K, Poonam P, Ashwini M, Ramakrishna S,
Deepti P. Antiviral activity of stearylamine against chikungunya
virus. Chem Physics Lipids, 2021; 235: 105049.
65. Wang C, Xiaoguang S, Huijuan S, Chuangnian Z, Xiaoli W, et
al. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic
chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity
against melanoma. Biomaterials, 2021; 268: 120579.
66. Luo MX, Hua S, Shang QY. Application of nanotechnology in
drug delivery systems for respiratory diseases. Mol Medicine
Reports, 2021; 23(5), pp. 1-17.
67. Kurakula M, Raghavendra N. Electrospraying: A Facile
Technology Unfolding the Chitosan based Drug Delivery and Biomedical
Applications. European Polymer J, 2021: 110326.
68. Vieira ACC, Luíse LC, Marina P, Sofia CL, Pedro José RN, et
al. Lipid nanoparticles coated with chitosan using a one-step association
method to target rifampicin to alveolar macrophages. Carbohydrate
Polymers, 2021; 252: 116978.
69. Topal GR, Maria M, Gergo P, Aniko S, Tamas FP, et al.
ApoE-Targeting Increases the Transfer of Solid Lipid Nanoparticles with
Donepezil Cargo across a Culture Model of the Blood–Brain Barrier.
Pharmaceutics, 2021; 13(1): 38.
70. Sabir F, Maimoona Q, Asim UR, Nasir MA, Gul MK, et al. An
Efficient Approach for Development and Optimization of Curcumin Loaded Solid
Lipid Nanoparticles’ Patch for Transdermal Delivery. J Microencapsulation,
2021; 1-34.
71. Devnarain N, Nawras O, Victoria OF, et al. Intrinsic stimuli
responsive nanocarriers for smart drug delivery of antibacterial agents-An in
depth review of the last two decades. Wiley Interdisciplinary Reviews:
Nanomedicine Nanobiotechnol., 2021; 13
(1): e1664.
72. Kurakula M, Basim P, Biopolymer-Lipid Hybrid Composites and
their Advances in Bio-imaging and Drug Delivery. J Radiol Med
Imaging, 2021; 4(1): 1041.
73. Hart N, Friederike A, Olivia MM. "From adsorption to
covalent bonding: Apolipoprotein E functionalization of polymeric nanoparticles
for drug delivery across the blood–brain barrier. Advanced therapeutics,
2021; 4(1): 2000092.
74. Witwer KW, Joy W. Extracellular vesicles versus synthetic
nanoparticles for drug delivery. Nature Rev Materials, 2021; pp. 1-4.
75. Pradhan D, Prativa B, Amit G, Goutam G, Goutam R. Recent
Advancement in Nanotechnology-Based Drug Delivery System Against Viral
Infections. AAPS Pharm Sci Tech., 2021; 22(1): 1-19.
76. Kurakula M, Koteswara R, Khushwant SY. Fabrication and
characterization of polycaprolactone-based green materials for drug delivery.
In Applications of Advanced Green Materials. Woodhead Publishing, 2021;
pp. 395-423.
77. Omidi Y, Nazanin K, Young K, Hossein O. Drug delivery and
targeting to brain tumors: considerations for crossing the blood-brain
barrier. Expert Rev Clin Pharmacol., 2021.
78. Angarita-Villamizar AV, Elsa RA, Ivonne LD, Leon DP.
Amphiphilic copolymers modified with oleic acid and cholesterol by combining ring
opening polymerization and click chemistry with improved amphotericin B loading
capacity. J Polymer Res., 2021; 28(1): 1-14.
79. Kurakula M, Koteswara R. Probiotics in Lung Cancer: An
Emerging Field of Multifarious Potential and Opportunities. Probiotic Res
Therapeutics, 2021; pp. 125-58.
80. Pérez-BY, Bianca de Carvalho FT, Eliana LFM, Ana MCR.
Biocompatible Lipid Polymer Cationic Nanoparticles for Antigen
Presentation. Polymers, 2021; 13(2): 185.